Q-omics provides the consensus-scored SNAP23 profile across patient tissues and cancer cell-line models. SNAP23 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SNAP23 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, SNAP23 RNA expression shows 20,533 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, LIHC, and UVM as cancer lineages where SNAP23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNAP23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNAP23 survival associations across molecular data types. SNAP23 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNAP23 RNA expression–survival associations across cancer types. High SNAP23 expression shows unfavorable associations in LGG, CESC and UVM, but favorable associations in SKCM, KIRC and UCEC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SNAP23 RNA expression.
This table summarizes SNAP23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SNAP23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNAP23 shows lower tumor expression in KICH, LUAD and LUSC and higher tumor expression in LIHC, HNSC and KIRC. The LIHC box plot shows higher SNAP23 RNA expression in tumor versus normal tissue (log2 FC = +0.801, t-test p < 0.001).
This table shows molecular features associated with SNAP23 in patient tissues and cancer cell lines. In patient samples, SNAP23 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNAP23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
